Founder & Chief Patient Officer - INNOMAVEN CONSULTING
(2023-02)
Patient strategy and innovation advisor, driving commercial success through patient insights and digital tools.
- Big Pharma: Collected cross-functional insights by creating a breast cancer advocate council to test launch tactics. Developed pre-launch market shaping strategies, patient access trainings, and strategic planning.
- Big Pharma: Developed a Launch Excellence tool centered on the patient journey to orchestrate a $3B oncology portfolio's launch readiness. Led workstream to design a frictionless onboarding patient experience with a welcome kit and other Patient Support Services (PSS) offerings.
- Patient Advocacy Group: Led multiple patient journey research on the experience of Black women living with Multiple Sclerosis and Lupus. Identified systemic and emotional barriers and opportunities. Ran ideation sprints with Pharma partners on health equity & access strategies.
- Leveraged AI and vibe coding to develop an innovative patient journey capture tool for researchers but free for patients. Currently in beta testing mode.
Innovation Lead (Americas Operating Board) - HEALTHCARE BUSINESSWOMEN'S ASSOCIATION (HBA)
(2023-06)
- Launched and marketed the Patient Centricity Industry Playbook in the HBA Academy along with other education resources; recognized with the Everest Award.
- Served as Global Deputy Chair (Patient Centricity Affinity Group) and HBA Patient Centricity ambassador on how to amplify the patient voice; spearheaded Patient Centricity Industry Playbook; recognized with the Marie Curie Award (x2) for innovation and impact.
- Moderated and oversaw end-to-end development of 3 successful educational events (Paving the Way for Equity, Rebranding Cancer, Dense Breast Health) as Educational Events Lead (Northern New Jersey); achieved record breaking attendance (150+ attendees).
US New Products Lead, Neuroscience - NOVARTIS
(2021-07 - 2023-01)
Responsible for $7B neurodegeneration portfolio (e.g., ALS, Huntington's, Parkinson's). Led matrix team (Market Access, Medical, R&D) on US asset strategy, market shaping, and BD&L evaluations.
- Uncovered an additional $700M opportunity (to $1.5B) for a Myasthenia Gravis asset by championing US HCP TPP testing that confirmed 2L vs. 4L positioning, then securing Global R&D Leadership buy-in to adjust the TPP and Ph2 development plan accordingly.
- Led US commercial strategy for 2 early-stage ALS assets (BLZ945, VHB937): value proposition, forecast, market landscape, TPP testing, customer segmentation, market access, patient advocacy landscape, etc.
- Successfully secured "go" investment decision from the Neuroscience Leadership Team for 2 new programs (~$2B sales potential); led rigorous due diligence, customer research, and cross-functional endorsement.
Director of Innovation, US AIMOVIG Marketing, Neuroscience - NOVARTIS
(2020-08 - 2021-07)
Recruited to define and lead the commercial vision & strategy for the Novartis/Amgen alliance in a crowded migraine market. Responsible for 2 direct reports and driving cross-functional alignment with Amgen.
- Designed an eCommerce strategy leveraging a telemedicine vendor and direct-to-patient (DTP) distribution integration to accelerate therapy access. Ultimately led to the 2025 launch of COSENTYX's DTP platform.
- Designed a novel HCP omnichannel strategy with potential for $1M+ savings in Year 1; established new brand impact KPIs, metrics, and analytics to measure impact.
- Created new customer journey archetypes, targeted messages, and digital marketing campaign that deliver an end-to-end enhanced customer experience against a new competitor's digital-first launch.
Launch Lead, US VYNDAMAX Marketing, Rare Diseases / Cardiology - PFIZER
(2019-01 - 2020-08)
Led cross-functional launch of a $6B ATTR-CM blockbuster and award-winning Marketing innovations.
- Set the team vision & culture, oversaw cross-functional strategies (Marketing, Market Access, Sales, etc), headed "Mission Control Center" during FDA approval, and reported KPIs and updates to senior leadership.
- Achieved HCP full promotional launch within 2 days of FDA approval (Webex with ~450 sales reps).
- Achieved $79M US sales in 1st quarter ($60M ahead of expectations, source: seekingalpha.com).
- Earned recognition for leading marketing innovations (e.g., on-demand video for peer-to-peer education, patient-originated social content) and selected for the Marketing Executive Externship at YouTube.
Director / Senior Manager, US Planning & Innovation, Oncology - PFIZER
(2014-10 - 2018-12)
Launch expert and strategic advisor to US Oncology Leadership & Commercial Teams (e.g., 5-year strategic plans, innovative analytics and capabilities, strategic partnerships, marketing & sales optimization).
- Launch: Spearheaded Pfizer's new Launch Excellence capability (achieved $1.5M savings in 2 years) by creating an industry-best Launch Playbook designed to scale across all TA's. Led 3 oncology launches: SUTENT (renal), TALZENNA (breast), DAURISMO (hematology).
- Strategy & analytics: measured & optimized SUTENT (renal) growth strategy through account prioritization (grew top 30 accounts by 20%), designed first-ever portfolio GPO strategy that catapulted IBRANCE (breast) launch uptake in the Community HCP segment.
- Marketing: Launched new MYLOTARG (AML) HCP website with customer insights, led analytics and message development of XALKORI (lung) flashcard for Key Account Managers to discuss diagnostic testing challenges.
- Innovation: Led a Google AI pilot using geolocation to support starting and staying on therapy, partnered with 4 diagnostics labs improve ALK testing nationally using innovative analytics and process improvement.
Engagement Manager - McCANN HEALTH CONSULTING
(2013 - 2014)
Advised F500 Pharma clients on commercial strategies and insights (e.g., oncology BD & portfolio strategy, pricing & market access strategy, global patient journey mapping, omnichannel marketing, analytical modeling). Responsible for client deliverables, business development, culture building, and developing junior consultants.
Senior Analyst - CDM NEW YORK
(2011 - 2013)
Management consulting advising F500 Pharma clients on commercial strategies and insights (e.g., oncology BD & portfolio strategy, pricing & market access strategy, global patient journey mapping, omnichannel marketing, analytical modeling). Responsible for client deliverables, business development, culture building, and developing junior consultants.
Consultant - IQVIA CONSULTING
(2009 - 2011)
Management consulting advising F500 Pharma clients on commercial strategies and insights (e.g., oncology BD & portfolio strategy, pricing & market access strategy, global patient journey mapping, omnichannel marketing, analytical modeling). Responsible for client deliverables, business development, culture building, and developing junior consultants.
